Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.60 |
| ▸ | IGF1R | P08069 | 5/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753980 | 0.82 | AXL (0.53) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL8323804 | 0.81 | JAK2 (0.62) | CAMKK2IGF1RPDPK1AXLCDK8 | |
| SCHEMBL13753938 | 0.81 | DYRK1A (0.59) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL1487600 | 0.81 | CAMKK2 (0.79) | CAMKK2IGF1RAXLCDK8TNIK | |
| SCHEMBL13746109 | 0.80 | CAMKK2 (0.55) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL8321970 | 0.80 | CCNT1 (0.51) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL8323355 | 0.79 | CAMKK2 (0.61) | CAMKK2IGF1RAXLCDK8TNIK | |
| SCHEMBL8321704 | 0.79 | MAPK8 (0.55) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL12829925 | 0.78 | SGK1 (0.68) | CAMKK2PDPK1AXLCDK8TNIK | |
| SCHEMBL13745689 | 0.77 | PTGS2 (0.36) | CAMKK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885IGF1R 1197/4885PDPK1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.